ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-OR18

Benefits of Icosapent Ethyl Across a Range of Baseline Renal Function in Patients with Established Cardiovascular Disease or Diabetes: Results of REDUCE-IT RENAL

Session Information

Category: CKD (Non-Dialysis)

  • 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

  • Majithia, Arjun, Brigham and Women's Hospital, Boston, Massachusetts, United States
  • Bhatt, Deepak L., Brigham and Women's Hospital, Boston, Massachusetts, United States
  • Friedman, Allon N., Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Miller, Michael, University of Maryland School of Medicine, Baltimore, Maryland, United States
  • Steg, Philippe Gabriel, Hopital Bichat - Claude-Bernard, Paris, Île-de-France, France
  • Brinton, Eliot A., Utah Lipid Center, Salt Lake City, Utah, United States
  • Jacobson, Terry A., Emory University School of Medicine, Atlanta, Georgia, United States
  • Ketchum, Steven B., Amarin Pharma Inc, Bridgewater, New Jersey, United States
  • Juliano, Rebecca A., Amarin Pharma Inc, Bridgewater, New Jersey, United States
  • Jiao, Lixia, Amarin Pharma Inc, Bridgewater, New Jersey, United States
  • Doyle, Ralph T., Amarin Pharma Inc, Bridgewater, New Jersey, United States
  • Granowitz, Craig B., Amarin Pharma Inc, Bridgewater, New Jersey, United States
  • Budoff, Matthew Jay, University of California Los Angeles, Los Angeles, California, United States
  • Mason, Preston, Brigham and Women's Hospital, Boston, Massachusetts, United States
  • Tardif, Jean-Claude, Institut De Cardiologie de Montreal, Montreal, Quebec, Canada
  • Boden, William E., VA Boston Healthcare System, West Roxbury, Massachusetts, United States
  • Ballantyne, Christie, Baylor College of Medicine, Houston, Texas, United States

Group or Team Name

  • REDUCE-IT Investigators
Background

Chronic kidney disease is associated with adverse outcomes among patients with established cardiovascular disease (CVD) or diabetes. Medications for treatment of CVD among patients with low estimated glomerular filtration rate (eGFR) may be ineffective.

Methods

The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) randomized patients with CVD or diabetes and one additional risk factor to treatment with icosapent ethyl or placebo. Patients from REDUCE-IT were categorized by prespecified eGFR categories for analysis of the effect of icosapent ethyl (IPE) on the primary endpoint (composite of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, coronary revascularization, or unstable angina) and key secondary endpoint (a composite of CV death, nonfatal MI, or nonfatal stroke). In post hoc analysis, patients were categorized by additional eGFR cutoffs consistent with current medical guidelines.

Results

Among the 8179 REDUCE-IT patients, median baseline eGFR was 75 mL/min/1.73m2 (range: 17 to 123 mL/min/1.73m2). There were no meaningful changes in median eGFR for IPE versus placebo across study visits. IPE benefit was consistent across baseline eGFR for the primary (Figure) and key secondary endpoints. The numerical reduction in CV death was greatest in the eGFR <60 mL/min/1.73m2 group (IPE: 7.6%; placebo: 10.6%; HR 0.70, 95%CI 0.51, 0.95, p=0.02). The rate of microalbuminuria in adverse event reporting was lower among IPE-treated patients (0.1% versus 0.3%, p=0.01).

Conclusion

In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories.

Funding

  • Commercial Support